Partner Nate Lacktman and Senior Counsel Thomas Ferrante were quoted in an mHealthIntelligence article, “FDA OKs mHealth App That Uses AI to Spot Strokes, Alert Specialists,” about what the Bipartisan Budget Act of 2018’s elimination of originating-site restrictions for telestroke services will mean for health care systems and institutions with established stroke programs.
The FDA recently approved an mHealth application, Viz.AI, which uses artificial intelligence software to analyze CT scans for signs of a stroke, then sends a message to a neurologist. It contains specially-designed mobile units that can start treatment when transmitted to the patient’s location, and telestroke platforms that allow health care providers to reach neurologists who are based anywhere.
In conjunction with this news, mHealthIntelligence featured Lacktman and Ferrante’s comments from the telestroke section of their recent Health Care Law Today blog post, which analyzes the new federal funding bill: “Allowing more qualified originating sites, such as the patient’s home, ambulances and mobile stroke units, will provide broader options for health care systems that do not have constant access to a neurologist and allow institutions with established stroke programs opportunities for destination medicine and new patients.”
